The Food and Drug Administration has approved Boehringer Ingelheim, Inc.'s Stiolto Respimat (tiotropium bromide and olodaterol), a once-daily inhaler meant to treat obstructed airflow in patients, the company announced Tuesday.
The complex issue of prescription drug abuse and access are not receiving the comprehensive approach that they deserve and greater collaboration is needed among all stakeholders to help find solutions. That was a key message that National Association of Chain Drug Stores CEO Steve Anderson and U.S. Pain Foundation president Paul Gileno shared in a joint op-ed published Tuesday in The Tampa Tribune.
In lead-up to Thursday’s Senate Finance Committee hearing, “A Pathway to Improving Care for Medicare Patients with Chronic Conditions,” the National Association of Chain Drug Stores submitted comments highlighting pharmacy’s role in helping patients manage their chronic conditions.